Logo wahanariau.com
  2. Teva pharmaceutical

Teva pharmaceutical

Index
Globenewswire

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Rabu, 19 Agustus 2026 - 21:48:36 Wib
Globenewswire

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

Selasa, 11 Agustus 2026 - 21:24:55 Wib
Globenewswire

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Rabu, 29 Juli 2026 - 20:52:00 Wib
Globenewswire

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Kamis, 09 Juli 2026 - 22:23:52 Wib
Globenewswire

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Selasa, 07 Juli 2026 - 21:38:30 Wib
Globenewswire

Teva Releases Q2 2026 Aide Memoire

Jumat, 19 Juni 2026 - 22:07:17 Wib
Globenewswire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Jumat, 19 Juni 2026 - 22:06:43 Wib
Globenewswire

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Jumat, 19 Juni 2026 - 22:06:02 Wib
Globenewswire

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Kamis, 11 Juni 2026 - 20:02:08 Wib
Globenewswire

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Senin, 08 Juni 2026 - 21:02:23 Wib
Globenewswire

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Kamis, 04 Juni 2026 - 20:50:43 Wib
Globenewswire

Teva to Present at the Goldman Sachs Global Healthcare Conference

Selasa, 02 Juni 2026 - 19:10:43 Wib
Globenewswire

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Kamis, 21 Mei 2026 - 22:34:10 Wib
Globenewswire

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

Senin, 18 Mei 2026 - 21:05:42 Wib
Globenewswire

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Senin, 18 Mei 2026 - 21:03:29 Wib
Globenewswire

Teva to Present at the BofA Securities Health Care Conference

Selasa, 05 Mei 2026 - 22:17:45 Wib
Globenewswire

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

Kamis, 30 April 2026 - 23:31:17 Wib
Globenewswire

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

Rabu, 29 April 2026 - 23:07:43 Wib
Globenewswire

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

Rabu, 29 April 2026 - 23:06:45 Wib
Globenewswire

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

Rabu, 15 April 2026 - 21:53:02 Wib
Globenewswire

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

Selasa, 14 April 2026 - 21:12:27 Wib
Globenewswire

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Senin, 30 Maret 2026 - 22:26:49 Wib
Globenewswire

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

Rabu, 04 Maret 2026 - 05:40:38 Wib
Globenewswire

Teva to Present at the Upcoming Investor Conferences in March

Rabu, 25 Februari 2026 - 06:28:43 Wib
Globenewswire

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Senin, 23 Februari 2026 - 11:54:59 Wib